Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01239134 | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | PHASE1 | COMPLETED | 10 | — | — | Oct 1, 2010 | Sep 1, 2018 | Aug 3, 2025 | 1 | United States |
Any adverse change in health or side effect from the initiation of the study drug dose through completion or premature withdrawal
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
Any adverse change in health or side effect from the initiation of the study drug dose through completion or premature withdrawal
| Arm | Type | Description |
|---|---|---|
| TRX518 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TRX518 | BIOLOGICAL | Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody |
Inclusion Criteria (Parts B \& C): * 18 years or older * Histologically confirmed unresectable Stage III or Stage IV malignant melanoma, or other solid tumor malignancies * Failed to respond to or relapsed following standard treatment, declined or was not eligible for standard treatment. * Expected...